Savoia Anna, Kunishima Shinji, De Rocco Daniela, Zieger Barbara, Rand Margaret L, Pujol-Moix Nuria, Caliskan Umran, Tokgoz Huseyin, Pecci Alessandro, Noris Patrizia, Srivastava Alok, Ward Christopher, Morel-Kopp Marie-Christine, Alessi Marie-Christine, Bellucci Sylvia, Beurrier Philippe, de Maistre Emmanuel, Favier Rémi, Hézard Nathalie, Hurtaud-Roux Marie-Françoise, Latger-Cannard Véronique, Lavenu-Bombled Cécile, Proulle Valérie, Meunier Sandrine, Négrier Claude, Nurden Alan, Randrianaivo Hanitra, Fabris Fabrizio, Platokouki Helen, Rosenberg Nurit, HadjKacem Basma, Heller Paula G, Karimi Mehran, Balduini Carlo L, Pastore Annalisa, Lanza Francois
Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy; Department of Medical Sciences, University of Trieste, Trieste, Italy.
Hum Mutat. 2014 Sep;35(9):1033-45. doi: 10.1002/humu.22607. Epub 2014 Jul 15.
Bernard-Soulier syndrome (BSS) is a rare autosomal recessive bleeding disorder characterized by defects of the GPIb-IX-V complex, a platelet receptor for von Willebrand factor (VWF). Most of the mutations identified in the genes encoding for the GP1BA (GPIbα), GP1BB (GPIbβ), and GP9 (GPIX) subunits prevent expression of the complex at the platelet membrane or more rarely its interaction with VWF. As a consequence, platelets are unable to adhere to the vascular subendothelium and agglutinate in response to ristocetin. In order to collect information on BSS patients, we established an International Consortium for the study of BSS, allowing us to enrol and genotype 132 families (56 previously unreported). With 79 additional families for which molecular data were gleaned from the literature, the 211 families characterized so far have mutations in the GP1BA (28%), GP1BB (28%), or GP9 (44%) genes. There is a wide spectrum of mutations with 112 different variants, including 22 novel alterations. Consistent with the rarity of the disease, 85% of the probands carry homozygous mutations with evidence of founder effects in some geographical areas. This overview provides the first global picture of the molecular basis of BSS and will lead to improve patient diagnosis and management.
伯纳德-索利尔综合征(BSS)是一种罕见的常染色体隐性出血性疾病,其特征是糖蛋白Ib-IX-V复合物存在缺陷,该复合物是血管性血友病因子(VWF)的血小板受体。在编码糖蛋白1BA(GPIbα)、糖蛋白1BB(GPIbβ)和糖蛋白9(GPIX)亚基的基因中发现的大多数突变会阻止该复合物在血小板膜上表达,或者更罕见的是阻止其与VWF相互作用。因此,血小板无法黏附于血管内皮下层,且对瑞斯托霉素无凝集反应。为了收集有关BSS患者的信息,我们成立了一个BSS研究国际联盟,从而能够招募132个家庭(56个此前未报告)并进行基因分型。从文献中收集到另外79个家庭的分子数据后,目前已确定特征的211个家庭在糖蛋白1BA(28%)、糖蛋白1BB(28%)或糖蛋白9(44%)基因中存在突变。存在广泛的突变,有112种不同变体,包括22种新的改变。与该疾病的罕见性一致,85%的先证者携带纯合突变,在某些地理区域有奠基者效应的证据。本综述首次全面呈现了BSS的分子基础,并将有助于改善患者的诊断和管理。